BPA Off vs BPA On: Number of Participants With Opioid Prescriptions After Discharge

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.175	0.168	0.182	wilson	ClinicalTrials.gov
Risk in group 2	0.186	0.179	0.193	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.011	-0.0212	-0.000714	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.941	0.889	0.996	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.929	0.866	0.995	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on BPA Off than on BPA On	91.3	47.2	1,400	from the risk difference interval	ClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	BPA Off	No BPA message is displayed to providers.	1,870	10,686	OG000	ClinicalTrials.gov
Group 2	BPA On	BPA message is displayed to providers based on patient opioid intake as reported in the EHR.~BPA: At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.	2,046	11,003	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Number of Participants With Opioid Prescriptions After Discharge	ClinicalTrials.gov
Description	Number of participants with opioid prescriptions after discharge as recorded in the electronic health record	ClinicalTrials.gov
Time frame	Day of discharge +1 until 28 days after discharge	ClinicalTrials.gov
Population		ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Best Practice Alert for Opioid Prescribing	ClinicalTrials.gov
NCT number	NCT04446975	ClinicalTrials.gov
Phases	NA	ClinicalTrials.gov
Conditions	Opioid Use	ClinicalTrials.gov
Interventions	BPA	ClinicalTrials.gov
Lead sponsor	University of Colorado, Denver	ClinicalTrials.gov
Results first posted	2024-03-04	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT04446975?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.